Market Research Logo

FirstWord

FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

   
  • Medical Affairs Reputations (EU5) [Melanoma]

    ... things in the EU5 countries. Oncologists gave it the highest overall score and the highest performance and satisfaction ratings on most medical affairs services. Meanwhile, a rival team has done just the opposite, earning the ... Read More

  • Market Access Impact (EU5) [Haemophilia B]

    ... are willing to consider them, so there’s room for brands to grow. To seize that opportunity, you need to understand the market barriers that are preventing doctors from prescribing your brand, and address the ones ... Read More

  • Market Access Impact (EU5) [Asthma/COPD]

    ... to a handful of brands, putting the market leaders even further ahead. Meanwhile some brands have a bigger problem: doctors aren’t prescribing them because they don’t know they exist. Market Access Impact: Asthma/COPD (EU5) shows ... Read More

  • Market Access Impact (US) [Parkinson's Disease]

    ... the 11 Parkinson’s disease treatments we asked them about are losing market share because of barriers. High cost and market access problems are the main culprits, but understanding the unique combination of barriers and competitive ... Read More

  • Targeted Therapies in Asthma [2017]: Bulletin #2

    ... severe asthma treatment landscape. Topics covered include; Novartis announcing the results from the 'Still Fighting for Breath' survey which demonstrates that despite the widespread availability of oral and inhaled treatments, asthma still places a huge ... Read More

  • Prostate Cancer [2016]: Bulletin #3

    ... STAMPEDE trials investigating J&J’s Zytiga (abiraterone) plus prednisone, in combination with androgen deprivation therapy (ADT) in patients with hormone-naïve prostate cancer (HNPC); KOL views on the results published in the Cancer Discovery journal which suggest ... Read More

  • Market Access Impact (US) [MS]

    ... being healthy, market barriers affect nearly 1 in 5 prescriptions. This isn’t all bad news for some brands, but others are losing out on market share gains. One of the new kids on the block ... Read More

  • NPS+ (EU5) [NSCLC]

    ... achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? NPS+ NSCLC (EU5) ... Read More

  • Psoriasis [2017]

    ... psoriasis, is there room for novel products, such as the anti-interleukin-(IL)-17 mAbs and next-generation anti-IL23 mAbs? What about recently approved products, such as Siliq/Kyntheum (brodalumab), and Tremfya (guselkumab; Janssen/MorphoSys)? Clinical and commercial differentiation will become ... Read More

  • Ovarian Cancer [2017]: Bulletin #1

    ... PARP inhibitor Zejula (niraparib) for the maintenance treatment of recurrent ovarian cancer that is in complete or partial response to platinum-based chemotherapy; the Phase III ARIEL3 trial of Clovis’ PARP inhibitor Rubraca (rucaparib) meeting its ... Read More

  • SLE: KOL Insight [2017]

    ... Rituxan/MabThera (rituximab), now experiencing biosimilar competition in Europe, is also used off-label. Despite these advances significant unmet need remains in the treatment of SLE. Novel products are on the horizon, including anifrolumab (BMZ/AstraZeneca), forigerimod (ImmunPharma) ... Read More

  • Market Access Impact (US) [Asthma/COPD]

    ... roughly 55% of doctors can’t prescribe certain brands because they’re either too expensive, or not available of formularies. Not all brands lose out, though. Two of the leading treatments get a market share bump of ... Read More

  • NPS+ (EU5) [Growth Hormone Deficiency]

    ... some brands are achieving greater levels of loyalty and satisfaction than others – but why? What are the key factors driving physician choice and how does each of the leading brands compare to its competitors? ... Read More

  • Multiple Myeloma: KOL Insight [2017]

    ... current range of treatment options – such as Celgene’s Revlimid and Takeda’s Velcade, and combination regimens of various therapies – are well established, unmet needs persist in the market for safe and effective drugs that ... Read More

  • Medical Affairs Reputations (US) [Cancer Pain]

    ... a lacklustre performance in the past 6 months. Their ratings on individual services barely crept into positive territory, and even though they’re contacting doctors a little too often, they’re failing to deliver the information doctors ... Read More

  • Medical Affairs Reputations (EU5) [Cancer Pain]

    ... turned in a disappointing performance in the past 6 months. Their ratings on individual services barely crept above neutral, and they’re failing to deliver the information doctors need. Nevertheless, doctors are open to more frequent ... Read More

  • Medical Affairs Reputations (US) [Melanoma]

    ... only did they earn the highest overall scores, the oncologists we surveyed gave them the highest performance and satisfaction ratings on almost every medical affairs service we asked about. This report reveals how your team ... Read More

  • Hepatitis C [2016]: Bulletin #3

    ... results of its triple combination JNJ-4178 (simeprevir/odalasvir/AL-335) in an ongoing Phase II study; AbbVie announcing positive data from two Phase III studies, ENDURANCE-3 and EXPEDITION-1, with its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). Merck & Co. ... Read More

  • CAR-T Disease Outlook [2017]

    ... leukaemia (ALL) and non-Hodgkin lymphoma (NHL) with high unmet needs. How will the impressive efficacy and safety of these therapies pan out in the long-term? Key opinion leaders (KOLs) explore the clinical challenges and opportunities ... Read More

  • Charting MSL Activity and Performance (2017)

    ... (MSL) professionals in the US and EU5 which reveals the changing face of MSL activity and the key engagement strategies and performance metrics that are being employed today. Building on the ground breaking 2015 Survey, ... Read More

  • Market Access Impact (US) [Haemophilia A]

    ... 8 brands we surveyed have nearly equal market share. Understanding the market barriers that prevent doctors from prescribing your brand is essential if you want to build a lasting competitive advantage. Learn how 7 barriers ... Read More

  • Market Access Impact (EU5) [Haemophilia A]

    ... for several of the brands we surveyed are very close. Understanding the market barriers that prevent doctors from prescribing your brand is essential if you want to build a lasting competitive advantage. Learn how 7 ... Read More

  • Market Access Impact (EU5) [CLL]

    ... is clearly popular and others are playing ‘catch-up’ on the market share stakes – but what difference would it make if the landscape shifted and non-clinical constraints such as cost, availability, administrative restrictions, institutional guidelines, ... Read More

  • Biomarkers and Companion Diagnostics - Payer views

    ... to realising the personalised medicines agenda. They support clinician decision making and are cost efficient for payers. But payers identify challenges around evidence of clinical utility, inconsistent practice between - and within – countries, and ... Read More

  • Medical Affairs Reputations (US) [MS]

    ... to the doctors on the receiving end? According to this latest survey, satisfaction levels are adequate but one in five physicians suggest that medical affairs teams could do better at providing specific information. Is ‘satisfactory’ ... Read More

4 5 6 7 9 11 12 13

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook